XML 31 R15.htm IDEA: XBRL DOCUMENT v3.25.0.1
Marketable Securities
12 Months Ended
Dec. 31, 2024
Marketable Securities  
Marketable Securities

7. Marketable Securities

Available-for-sale debt securities were classified on the consolidated balance sheets at fair value as follows:

December 31,

December 31,

    

2024

2023

Cash and cash equivalents

$

1,993

$

4,729

Marketable securities

92,198

71,601

Total

$

94,191

$

76,330

Available-for-sale debt securities consisted of the following:

December 31, 2024

Amortized Cost

    

Gross Unrealized Gains

    

Gross Unrealized Losses

Fair Value

Corporate debt securities

$

82,611

$

161

$

(93)

$

82,679

U.S. Treasury securities

Government-sponsored securities

6,572

(12)

6,560

Commercial paper

4,953

1

(2)

4,952

Total

$

94,136

$

162

$

(107)

$

94,191

December 31, 2023

Corporate debt securities

$

41,610

$

47

$

(45)

$

41,612

U.S. Treasury securities

30,189

8

30,197

Government-sponsored securities

4,517

4

4,521

Total

$

76,316

$

59

$

(45)

$

76,330

The contractual maturities of available-for-sale debt securities were as follows:

December 31,

December 31,

    

2024

2023

Matures within one year

$

50,469

$

61,672

Matures after one year through five years

43,722

14,658

Total

$

94,191

$

76,330

The unrealized losses on the Company’s available-for-sale debt securities were immaterial as of December 31, 2024 and December 31, 2023. The Company did not hold available-for-sale debt securities as of December 31, 2022.

There were no sales of marketable securities during the years ended December 31, 2024 or 2023. Net unrealized holding gains or losses for the period that have been previously included in accumulated other comprehensive income were not material to the Company’s consolidated statement of operations.

The Company did not record any allowances for credit losses to adjust the fair value of available-for-sale debt securities during the year ended December 31, 2024 or 2023. The Company reviews its investments for other-than-temporary impairment whenever the fair value of an investment is less than amortized cost and evidence indicates that an investment’s carrying amount is not recoverable within a reasonable period of time. To determine whether an impairment is other-than-temporary, the Company considers whether it has the ability and intent to hold the investment until a market price recovery and considers whether evidence indicating the cost of the investment is recoverable outweighs evidence to the contrary. The Company generally does not intend to sell any investments prior to recovery of their amortized cost basis for any investment in an unrealized loss position. As such, the Company did not hold any securities with other-than-temporary impairment as of December 31, 2024 or 2023.